Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1948 1
1950 2
1951 3
1952 3
1953 3
1954 5
1955 8
1956 8
1957 11
1958 9
1959 18
1960 10
1961 9
1962 9
1963 12
1964 9
1965 10
1966 8
1967 4
1968 9
1969 7
1970 8
1971 4
1972 3
1973 7
1974 4
1975 8
1976 17
1977 17
1978 20
1979 10
1980 13
1981 12
1982 12
1983 26
1984 24
1985 23
1986 32
1987 22
1988 29
1989 35
1990 31
1991 29
1992 30
1993 33
1994 25
1995 23
1996 35
1997 33
1998 41
1999 28
2000 35
2001 35
2002 25
2003 27
2004 29
2005 39
2006 36
2007 37
2008 35
2009 27
2010 41
2011 42
2012 50
2013 63
2014 62
2015 82
2016 79
2017 88
2018 88
2019 98
2020 91
2021 83
2022 75
2023 67
2024 54
2025 39

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,058 results

Results by year

Filters applied: . Clear all
Page 1
Biotinidase Deficiency.
Wolf B. Wolf B. 2000 Mar 24 [updated 2023 May 25]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. 2000 Mar 24 [updated 2023 May 25]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 20301497 Free Books & Documents. Review.
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Subbiah V, Sahai V, Maglic D, Bruderek K, Touré BB, Zhao S, Valverde R, O'Hearn PJ, Moustakas DT, Schönherr H, Gerami-Moayed N, Taylor AM, Hudson BM, Houde DJ, Pal D, Foster L, Gunaydin H, Ayaz P, Sharon DA, Goyal L, Schram AM, Kamath S, Sherwin CA, Schmidt-Kittler O, Jen KY, Ricard F, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Casaletto JB. Subbiah V, et al. Among authors: wolf bb. Cancer Discov. 2023 Sep 6;13(9):2012-2031. doi: 10.1158/2159-8290.CD-23-0475. Cancer Discov. 2023. PMID: 37270847 Free PMC article.
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio AA, Bulku A, DiPietro L, Fridrich C, Frost A, Giordanetto F, Hamilton EP, Harris K, Holliday M, Hunter TL, Iskandar A, Ji Y, Larivée A, LaRochelle JR, Lescarbeau A, Llambi F, Lormil B, Mader MM, Mar BG, Martin I, McLean TH, Michelsen K, Pechersky Y, Puente-Poushnejad E, Raynor K, Rogala D, Samadani R, Schram AM, Shortsleeves K, Swaminathan S, Tajmir S, Tan G, Tang Y, Valverde R, Wehrenberg B, Wilbur J, Williams BR, Zeng H, Zhang H, Walters WP, Wolf BB, Shaw DE, Bergstrom DA, Watters J, Fraser JS, Fortin PD, Kipp DR. Varkaris A, et al. Among authors: wolf bb. Cancer Discov. 2024 Feb 8;14(2):240-257. doi: 10.1158/2159-8290.CD-23-0944. Cancer Discov. 2024. PMID: 37916956 Free PMC article.
S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms.
Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. Sabrina V, et al. Among authors: wolf b. Z Gastroenterol. 2022 Jan;60(1):e56-e130. doi: 10.1055/a-1589-7568. Epub 2022 Jan 18. Z Gastroenterol. 2022. PMID: 35042248 Free article. German. No abstract available.
A systematic review of anterior cruciate ligament reconstruction rehabilitation: part I: continuous passive motion, early weight bearing, postoperative bracing, and home-based rehabilitation.
Wright RW, Preston E, Fleming BC, Amendola A, Andrish JT, Bergfeld JA, Dunn WR, Kaeding C, Kuhn JE, Marx RG, McCarty EC, Parker RC, Spindler KP, Wolcott M, Wolf BR, Williams GN. Wright RW, et al. Among authors: wolf br. J Knee Surg. 2008 Jul;21(3):217-24. doi: 10.1055/s-0030-1247822. J Knee Surg. 2008. PMID: 18686484 Free PMC article.
Personalized Postprandial Glucose Response-Targeting Diet Versus Mediterranean Diet for Glycemic Control in Prediabetes.
Ben-Yacov O, Godneva A, Rein M, Shilo S, Kolobkov D, Koren N, Cohen Dolev N, Travinsky Shmul T, Wolf BC, Kosower N, Sagiv K, Lotan-Pompan M, Zmora N, Weinberger A, Elinav E, Segal E. Ben-Yacov O, et al. Among authors: wolf bc. Diabetes Care. 2021 Sep;44(9):1980-1991. doi: 10.2337/dc21-0162. Epub 2021 Jul 23. Diabetes Care. 2021. PMID: 34301736 Clinical Trial.
Impact of antibody Fc engineering on translational pharmacology, and safety: insights from industry case studies.
Brennan FR, Polli JR, Sathish J, Ramones M, Wolf B, Schlothauer T, Peters SJ, Maier CC, Ji C, Wensel DL, Witcher D, Ryan PC, Manetz TS, Flora A, Soper B, Fogal B, Dzielak L, Wang X, Shastri PN, Price K, Doyle M, Sharda N, Struthers M, Brinkhaus M, Balbino B, Stefanich E, Honda M, Andersen JT, Mitchell-Ryan S, Humphreys DP. Brennan FR, et al. Among authors: wolf b. MAbs. 2025 Dec;17(1):2505092. doi: 10.1080/19420862.2025.2505092. Epub 2025 Jul 7. MAbs. 2025. PMID: 40624840 Free PMC article. Review.
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, Cassier PA, Mir O, Eskens F, Tap WD, Rutkowski P, Chawla SP, Trent J, Tugnait M, Evans EK, Lauz T, Zhou T, Roche M, Wolf BB, Bauer S, George S. Heinrich MC, et al. Among authors: wolf bb. Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2. Lancet Oncol. 2020. PMID: 32615108 Clinical Trial.
2,058 results